Ribbon Acquisition is no longer a search-stage cash box. Public holders approved the long-pending combination with DRC Medicine and then redeemed almost the entire remaining public book, leaving a thin residual trust and a stub that now prices deal optionality rather than a funded redemption floor. The vehicle is a Cayman blank-check company listed on Nasdaq, led from Tokyo, and paired with a Japanese consumer-hygiene issuer that wants a United States listing more than it needs a large cash infusion that is no longer there.
The mid-year print still looked like a conventional small special purpose acquisition company. Trust interest covered most overhead. A sponsor affiliate note funded monthly extension deposits. A going-concern paragraph sat next to the late-January combination deadline. That picture is obsolete. The September shareholder meeting stripped the net-tangible-asset redemption constraint, approved a Cayman-to-Delaware move, and cleared the June business combination agreement. Holders then elected to take cash at a mid-ten redemption price, collapsing trust cash to a low-seven-figure stub. A same-week financing package with Meteora adds a large standby equity line, a discounted convertible note, and a prepaid forward. That package is the replacement capital stack now that the original offering proceeds are largely spoken for.
The investment debate is whether DRC Medicine can certify and commercialize a therapeutic-mask and diagnostics story at a three-hundred-fifty-million headline equity value after the cash that was supposed to fund trials has already left. Closing still requires remaining conditions. The next facts that resolve the case are the closing cash table, the first post-close share count, and whether the equity line is drawn immediately to replace redeemed trust proceeds.